Stock Financial Ratios, Dividends, Split History

CBOE / CBOE Holdings, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price104.62
Volume450,700.00
Market Cap ($M)11,784.48
Enterprise Value ($M)12,831.58
Book Value ($M)3,175.20
Book Value / Share28.23
Price / Book3.71
NCAV ($M)512.30
NCAV / Share4.55
Price / NCAV23.00
Share Statistics
Common Stock Shares Outstanding 112,741,217
Preferred Stock Shares Outstanding 0
Common Shares Outstanding 112,704,945
Weighted Average Number Of Shares Outstanding Basic 107,200,000
Weighted Average Number Of Diluted Shares Outstanding 107,500,000
Weighted Average Numberof Shares Outstanding Diluted Before Effectof Incremental Common Shares Attributableto Participating Nonvested Shareswith Nonforfeitable Dividend Rights 107,200,000
Scoring Models
Piotroski F-Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.09
Return on Assets (ROA)0.84
Return on Equity (ROE)1.26
Balance Sheet (mrq) ($M)
Assets5,328.20
Liabilities0.00
Quick Ration/a
Current Ratio1.33
Income Statement (mra) ($M)
Clearing Fees Revenue1,564,900,000.00
Market Data Revenue164,500,000.00
Other Sales Revenue Net26,600,000.00
Regulatory Fees Revenue291,500,000.00
Revenues2,229,100,000.00
Operating Income371.90
Net Income400.60
Earnings Per Share Basic3.70
Earnings Per Share Diluted3.69
Cash Flow Statement (mra) ($M)
Cash From Operations374.40
Cash from Investing-1,436.50
Cash from Financing-1,436.50
Identifiers and Descriptors
CUSIP12503M108
Central Index Key (CIK)1374310
Related CUSIPS
012503M10 12503M908 12503M958

Split History

Stock splits are used by CBOE Holdings, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

China Steps Up Support To Growth

2018-07-20 seekingalpha
Interesting policy action was taken in emerging markets today - with only China daring to ease further.

Nasdaq (NDAQ) Posts Mixed Q2 Volumes, Revenues Per Contract

2018-07-10 zacks
Nasdaq, Inc. (NDAQ - Free Report) has reported mixed volumes for second-quarter 2018. While U.S. equity options volume increased 8% year over year to 417 million contracts, European options and futures volumes registered 21.9 million contracts, down 1.4% year over year. However, revenues per contract for U.S. equity options remained flat year over year at 15 cents, although the same for European options and futures expanded 12. (2-0)

Intercontinental Exchange (ICE) Posts Record Volumes in Q2

2018-07-09 zacks
Intercontinental Exchange, Inc. (ICE - Free Report) has grossed record average daily volume (ADV) for Agriculture and Metals, which increased 13% year over year. Volumes in the second quarter were driven by better numbers in all the months of the quarter. The exchange operator witnessed record Oil ADV, increasing 2% year over year. While Euribor ADV improved 21% year over year, Gilt ADV was 29% higher. (4-0)

Why Is Cboe Global (CBOE) Down 7.5% Since its Last Earnings Report?

2018-06-04 zacks
It has been about a month since the last earnings report for Cboe Global Markets, Inc. (CBOE - Free Report) . Shares have lost about 7.5% in that time frame. (27-0)

Cboe Global (CBOE) Beats on Q1 Earnings, Revises Guidance

2018-05-07 zacks
Cboe Global Markets, Inc.’s (CBOE - Free Report) first-quarter 2018 adjusted earnings of $1.38 per share beat the Zacks Consensus Estimate of $1.27 by 8.7%. Moreover, the bottom line improved nearly 47% year over year. (104-0)

CUSIP: 12503M108